AnGes, Inc. (FRA:AJW)

Market Cap	127.30M +36.3%
Revenue (ttm)	4.71M +57.0%
Net Income	-147.78M
EPS	-0.45
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.2720
Previous Close	0.2680
Day's Range	0.2720 - 0.2720
52-Week Range	0.2280 - 0.6150
Beta	n/a
RSI	46.90
Earnings Date	Feb 10, 2026

About AnGes

AnGes, Inc. engages in the research and development of gene-based medicines. It develops HGF gene therapy product for the treatment of chronic arterial occlusive disease; NF-KB decoy oligonucleotide for chronic discogenic lumbar back pain; and DNA vaccines for the treatment of hypertension, as well as tie2 agonists for COVID-19/ARDS and drugs for chronic hepatitis B. The company was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. AnGes, Inc. was incorporated in 1999 and is headquartered in Ibaraki, Japan.

• Industry: Pharmaceutical Preparations
• Founded: 1999
• Employees: 55
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: AJW

Financial Performance

In 2024, AnGes's revenue was 643.00 million, an increase of 323.03% compared to the previous year's 152.00 million. Losses were -28.13 billion, 278.2% more than in 2023.

Financial numbers in JPY